Importance:
Glioma is the most commonly occurring malignant brain tumor in the United States, and its incidence varies by age, sex, and race or ethnicity. Survival after brain tumor diagnosis has been shown to vary by these factors.
Objective:
To quantify the differences in incidence and survival rates of glioma in adults by race or ethnicity.
Design, Setting, And Participants:
This population-based study obtained incidence data from the Central Brain Tumor Registry of the United States and survival data from Surveillance, Epidemiology, and End Results registries, covering the period January 1, 2000, to December 31, 2014. Average annual age-adjusted incidence rates with 95% CIs were generated by glioma histologic groups, race, Hispanic ethnicity, sex, and age groups. One-year and 5-year relative survival rates were generated by glioma histologic groups, race, Hispanic ethnicity, and insurance status. The analysis included 244 808 patients with glioma diagnosed in adults aged 18 years or older. Data were collected from January 1, 2000, to December 31, 2014. Data analysis took place from December 11, 2017, to January 31, 2018.
Results:
Overall, 244 808 patients with glioma were analyzed. Of these, 150 631 (61.5%) were glioblastomas, 46 002 (18.8%) were non-glioblastoma astrocytomas, 26 068 (10.7%) were oligodendroglial tumors, 8816 (3.6%) were ependymomas, and 13 291 (5.4%) were other glioma diagnoses in adults. The data set included 137 733 males (56.3%) and 107 075 (43.7%) females. There were 204 580 non-Hispanic whites (83.6%), 17 321 Hispanic whites (7.08%), 14 566 blacks (6.0%), 1070 American Indians or Alaska Natives (0.4%), and 5947 Asians or Pacific Islanders (2.4%). Incidences of glioblastoma, non-glioblastoma astrocytoma, and oligodendroglial tumors were higher among non-Hispanic whites than among Hispanic whites (30% lower overall), blacks (52% lower overall), American Indians or Alaska Natives (58% lower overall), or Asians or Pacific Islanders (52% lower overall). Most tumors were more common in males than in females across all race or ethnicity groups, with the great difference in glioblastoma where the incidence was 60% higher overall in males. Most tumors (193 329 [79.9%]) occurred in those aged 45 years or older, with differences in incidence by race or ethnicity appearing in all age groups. Survival after diagnosis of glioma of different subtypes was generally comparable among Hispanic whites, blacks, and Asians or Pacific Islanders but was lower among non-Hispanic whites for many tumor types, including glioblastoma, irrespective of treatment type.
Conclusions And Relevance:
Incidence of glioma and 1-year and 5-year survival rates after diagnosis vary significantly by race or ethnicity, with non-Hispanic whites having higher incidence and lower survival rates compared with individuals of other racial or ethnic groups. These findings can inform future discovery of risk factors and reveal unaddressed health disparities.
Citing Articles
Suppression of FOXO1 activity by SIRT1-mediated deacetylation weakening the intratumoral androgen autocrine function in glioblastoma.
Cheng Y, Xiao Z, Cai W, Zhou T, Yang Z
Cancer Gene Ther. 2025; .
PMID: 40075208
DOI: 10.1038/s41417-025-00880-1.
Dual nuclear receptor 4A1 (NR4A1/NR4A2) ligands inhibit glioblastoma growth and target TWIST1.
Upadhyay S, Lee M, Zhang L, Oany A, Mikheeva S, Mikheev A
Mol Pharmacol. 2025; 107(2):100009.
PMID: 40023516
PMC: 11881746.
DOI: 10.1016/j.molpha.2024.100009.
A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging.
Vollmuth P, Karschnia P, Sahm F, Park Y, Ahn S, Jain R
Korean J Radiol. 2025; 26(3):246-268.
PMID: 39999966
PMC: 11865903.
DOI: 10.3348/kjr.2024.0982.
Tumour surface regularity predicts survival and benefit from gross total resection in IDH-wildtype glioblastoma patients.
Lin P, Pang J, Lin Y, Qin Q, Lv J, Zhou G
Insights Imaging. 2025; 16(1):42.
PMID: 39961919
PMC: 11833034.
DOI: 10.1186/s13244-025-01900-2.
Political economics in health and implications for neurosurgery diseases.
Han Y, Huang Y
Front Public Health. 2025; 12:1444249.
PMID: 39935745
PMC: 11811093.
DOI: 10.3389/fpubh.2024.1444249.
Pre-diagnostic risk factors for brain cancer incidence and survival: insights from the Golestan Cohort Study.
Rezanejad-Asl P, Roudsari P, Rezaei N, Sharafkhah M, Roshandel G, Poustchi H
BMC Cancer. 2025; 25(1):210.
PMID: 39920709
PMC: 11804039.
DOI: 10.1186/s12885-025-13642-x.
Increased nuclear expression of DNA damage inducible transcript 4 can serve as a potential prognostic biomarker in patients with gliomas: a study based on data mining and experimental tools.
Sadeghipour A, Fattahi F, Madjd Z, Tajik F, Sedaghati F, Saeednejad Zanjani L
Discov Oncol. 2025; 16(1):124.
PMID: 39915428
PMC: 11802953.
DOI: 10.1007/s12672-025-01865-0.
Cancers of the brain and central nervous system: global patterns and trends in incidence.
Filho A, Znaor A, Sunguc C, Zahwe M, Marcos-Gragera R, Figueroa J
J Neurooncol. 2025; .
PMID: 39883354
DOI: 10.1007/s11060-025-04944-y.
Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study.
Tunbekici S, Yuksel H, Acar C, Sahin G, Orman S, Majidova N
Cancers (Basel). 2025; 17(1.
PMID: 39796675
PMC: 11718784.
DOI: 10.3390/cancers17010046.
Differences in tumor size, clinical, demographic, and socioeconomic profiles of central nervous system tumors among a racially diverse cohort: A retrospective case-control study.
Kim K, Lew R, Higashihara T, Yamashita S, Pang M, Stafford M
Surg Neurol Int. 2025; 15():459.
PMID: 39777174
PMC: 11704430.
DOI: 10.25259/SNI_190_2024.
Coffee and tea consumption and glioma risk: a meta-analysis of cohort studies.
Pan J, Shao C, Tang H, Wu N
Front Nutr. 2024; 11:1506847.
PMID: 39737152
PMC: 11684387.
DOI: 10.3389/fnut.2024.1506847.
Clinical and Imaging Features of Head and Neck Metastasis of High-Grade Glioma: A Single-Center Case Series.
Eldaya R, Kaya D, Williams M, Calle S, Schellingerhout D
AJNR Am J Neuroradiol. 2024; 46(1):160-165.
PMID: 39667825
PMC: 11735445.
DOI: 10.3174/ajnr.A8521.
Dysregulation of Iron Homeostasis Mediated by FTH Increases Ferroptosis Sensitivity in TP53-Mutant Glioblastoma.
Huan X, Li J, Chu Z, Zhang H, Cheng L, Lun P
Neurosci Bull. 2024; .
PMID: 39666195
DOI: 10.1007/s12264-024-01322-y.
Impact of Nuclear Peripheral Chromatin Lamin LMNB1 Gene in the Proliferation and Migration of Glioma Cells.
Shi X, Zhang T, Li C, Guo C, Yang Q, Feng Y
Neurochem Res. 2024; 50(1):46.
PMID: 39636549
DOI: 10.1007/s11064-024-04298-3.
Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity.
Qin X, Zhang L, Liu J, Lu Y, Zhou F, Jin F
Stem Cells Int. 2024; 2024:1348269.
PMID: 39619148
PMC: 11606656.
DOI: 10.1155/2024/1348269.
miR-200 family as new potential prognostic factor of overall survival of patients with WHO G2 and WHO G3 brain gliomas.
Bilski M, Ciesielka M, Orzechowska M, Jarosz B, Calka P, Bilska S
Sci Rep. 2024; 14(1):29345.
PMID: 39592656
PMC: 11599569.
DOI: 10.1038/s41598-024-80656-z.
hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: and study.
Shadbad M, Baradaran B
Oncol Res. 2024; 32(12):1949-1958.
PMID: 39574474
PMC: 11576920.
DOI: 10.32604/or.2024.051569.
CRISPR targeting of mmu-miR-21a through a single adeno-associated virus vector prolongs survival of glioblastoma-bearing mice.
Nieland L, Vrijmoet A, Jetten I, Rufino-Ramos D, de Reus A, Breyne K
Mol Ther. 2024; 33(1):133-151.
PMID: 39563028
PMC: 11764731.
DOI: 10.1016/j.ymthe.2024.11.023.
The Inflammatory Characteristics of Symptomatic Glioma Associated With Poor Prognosis and Chemoresistance via Tumor Necrosis Factor Signaling Pathway.
Park J, Kim D, Sim J, Kim Y, Cho K, Moon J
Brain Tumor Res Treat. 2024; 12(4):237-244.
PMID: 39542520
PMC: 11570084.
DOI: 10.14791/btrt.2024.0035.
Precision Population Cancer Medicine in Brain Tumors: A Potential Roadmap to Improve Outcomes and Strategize the Steps to Bring Interdisciplinary Interventions.
Velu U, Singh A, Nittala R, Yang J, Vijayakumar S, Cherukuri C
Cureus. 2024; 16(10):e71305.
PMID: 39529768
PMC: 11552465.
DOI: 10.7759/cureus.71305.